Trial Profile
Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Carcinoid tumour; Pancreatic cancer
- Focus Therapeutic Use
- 28 Jan 2021 Status changed from active, no longer recruiting to completed.
- 23 Jan 2019 Planned End Date changed from 16 Aug 2020 to 16 Aug 2021.
- 23 Jan 2019 Planned primary completion date changed from 16 Aug 2019 to 16 Aug 2020.